Fig. 20.1 Various causes of LSC development In recent years, new techniques have begun to revolutionize the diagnosis, prognosis, and classification of leukemia. More recently, the introduction of high-speed analysis…
Aza C Supportive care Crossover No. of patients % No. of patients % No. of patients % No. evaluated 99 92 49 CR 7 7* 0 0 5 10…
Reference Regimen Patients (no.) Median age (years) ORR (%) CR (%) OS Kantarjian et al. [19] Clofarabine monotherapy 112 71 46 38 41 weeks Faderl et al. [26]a Clofarabine +…
Fig. 12.1 The molecular mechanism of action of ATO in APL. ATO binds to the B2 domain of the PML moiety of the PML-RARα protein, inducing binding of UBC9 followed…
Author Year IO Dose No. of patients Response (%) Advani A 2010 Single 1.8 mg/m2 FL: 22 FL: 68 DLBCL:26 DLBCL: 15 Ogura M 2010 Single 1.8 mg/m2 FL: 10…
Related posts: Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results Clinical Use of Clofarabine for Adults and Children with Leukemia Nelarabine Rituximab and Alemtuzumab for Chronic Lymphocytic…
Fig. 6.1 Treatment strategy of B-CLL by the GCLLSG. Abbreviations: FCR fludarabine, cyclophosphamide, and rituximab, BR bendamustine and rituximab, R-idelalisib rituximab and idelalisib, SCT stem cell transplantation, G-CLB obinutuzumab and…
Fig. 7.1 Chest X-ray at presentation showing widening mediastinum Fig. 7.2 CT chest at presentation showing the disease starting at the left neck to the lower mediastinum with pleural and…
Fig. 1.1 Pre-chemotherapy PET/CT scan (axial slices) demonstrating the extent of disease in the right neck Fig. 1.2 Pre-chemotherapy PET/CT scan (coronal view) demonstrating the extent of disease Pathology The…
Fig. 11.1 Initial staging MRI of case 1 In the 2008 WHO criteria [3], update of the REAL classification [2], “nasal” NKTCL was defined as a disease occurring in the…
